Aurelie Gautier
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Efficacy and Safety of Ligelizumab in Individuals With Confirmed Peanut Allergy.
Journal: Allergy
Published: June 10, 2025
Model-Informed Drug Development for Ligelizumab in Patients With Chronic Spontaneous Urticaria.
Journal: CPT: pharmacometrics & systems pharmacology
Published: November 29, 2024
Model-based comparisons of post-treatment free IgE and FEV1 between omalizumab asthma dosing tables in the United States and European Union.
Journal: British journal of clinical pharmacology
Published: April 05, 2024
The rationale for development of ligelizumab in food allergy.
Journal: The World Allergy Organization journal
Published: May 05, 2022
Pharmacokinetics and exposure-efficacy relationships of omalizumab in patients with nasal polyps.
Journal: Pulmonary pharmacology & therapeutics
Published: April 16, 2021
Regional brain mGlu5 receptor occupancy following single oral doses of mavoglurant as measured by [11C]-ABP688 PET imaging in healthy volunteers.
Journal: NeuroImage
Published: September 07, 2020
Ligelizumab treatment for severe asthma: learnings from the clinical development programme.
Journal: Clinical & translational immunology
Published: May 07, 2020
Ethnic sensitivity assessment of pharmacokinetics and pharmacodynamics of omalizumab with dosing table expansion.
Journal: Drug metabolism and pharmacokinetics
Published: August 21, 2015
Showing 1-8 of 8
Last Updated: 09/26/2026